Anti-EGFR antibodies and antibody drug conjugates
US10098968B2 · kind B2 · utility
1Cited by
11References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 9, 2017 |
| Grant date | Oct 16, 2018 |
| Priority date | — |
| Expiry date | Nov 9, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.